Fischer Medical Ventures Chairman Outlines Business Segments

Date: September 16, 2026

The company organizes its business into three segments:

Radiology Business - TMIV Imaging

Built on proprietary imaging technology platform with university research roots
Comprehensive product portfolio organized around three strategic pillars: Diagnostics, Screening, and Interventional Radiology
Technology developed in-house with capability to scale beyond India and compete in global markets

Pillar 1: Diagnostics

Open MRI: AURIX (0.35T) - flagship product, cost-effective high-performance whole-body MRI systems
Open MRI: AURA (0.7T) - extends open architecture with advanced sequences (MR spectroscopy, diffusion tensor imaging, perfusion imaging)
Closed MRI: MICA/MICA Smart (1.5T, 32- or 16-channel) - cost-effective, zero boil-off platform
Closed MRI: QUIN (1.5T) - India's first helium-free 1.5T MRI system with 70cm bore
NEONA - compact, FDA-approved neonatal MRI system for NICU co-location, reduces RF power deposition by 50-70%, cuts acoustic noise by 80%, reduces imaging time by 50%, won Geneva Invention Award
Next-generation platforms: NEXA (3T flagship), N-NEXA (3T helium-less), NOVA (7T pre-clinical research) in development with regulatory approvals in progress
CT: CLARION range (32-, 64- and 128-slice plus wide-bore configuration) with liquid metal bearing X-ray tube and Aegis detector system
Digital Mammography and X-ray: Navigator DR CARE with amorphous silicon detector, Navigator 3000A with integrated 3D tomosynthesis
VISION 500 and VISION 800 digital radiography-ready X-ray systems (40kW and 80kW generators respectively)

Pillar 2: Screening

VEGA - highly optimized low-field system for rapid, contrast-free, radiation-free vascular imaging for cerebrovascular assessment and stroke-risk evaluation

Pillar 3: Interventional Radiology

Medharanya Suite (DRIS and DRIS+) - intraoperative MRI platform integrating augmented reality, AI/machine vision, Exoscope technology, MR spectroscopy, perfusion imaging, and diffusion tensor imaging
CLARION Intraoperative CT (91cm bore) - big-bore, rail-mounted CT system with wireless interventional control station

Differentiation Factors

Genuinely proprietary technology platform with 15+ year university-research lineage
Engineering innovations including zero boil-off and helium-free magnet designs
India's first indigenous MRI manufacturer
First-ever industry partner given a seat in World Federation of Neurosurgical Societies (WFNS)

Indonesia Expansion

Entered market in October 2024 with customized integrated solution for National Stop Tuberculosis Programme
4T4TB solution combining Diagnostics and Screening capabilities into "Trace-Test-Treat-Track" workflow
Combines portable handheld digital X-ray systems with AI-assisted image analysis and FMV Prime qPCR rapid molecular testing platform
Government programme backed by budget of up to USD 500 million (Rp 8 trillion)

Philippines Expansion

Subsidiary Time Medical Philippines Inc. installed first open and locally funded MRI at Bulacan Medical Centre in November 2025
PICA Open MRI system chosen for open architecture, helium-free permanent magnet design, and built-in teleradiology capability
As of 2022, Philippines had only around 160 MRI units nationally

Company Structure

Wholly owned subsidiary of Fischer Medical Ventures Limited
Focused on eliminating avoidable disease burden through AI-enabled screening and diagnostics

Core Product Verticals

Clinics 2.0 - specialty EHR and practice management
MIDAS - multi-spectral integrated diagnostic system
LIVE Dx - tele-diagnosis and community care platform
ATLAS - AI-powered healthcare analytics platform with "containerized" hybrid cloud system

Screening and Diagnostics - MIDAS/eHAP

Health Lounge and Health ATM 2.0 - multi-spectral, AI-powered screening kiosks
Includes AI fundus screening, AI multi-spectral oral cancer screening, AI-enabled thermal imaging for breast cancer, digital risk assessment for cervical cancer, cardio-pulmonary screening, diabetic neuropathy and foot-risk screening, AI-powered non-invasive cardiac risk profiling

Tele-Health and Community Care - LIVE Dx

AI-enabled health device integration platform and tele-health platform
24/7 video/voice/chat doctor consultations, online appointment booking, medical history, drug reminders, integration with third-party wellness apps

Structured Disease Programs

Tuberculosis program: 4T4TB methodology (Trace, Test, Treat, Track)
Cancer program: SHIELD methodology (Screen, Highlight, Investigate, Empower, Long-term Monitoring, Develop)

Analytics and Digital Twin

ATLAS platform moving toward full "Digital Twin" capability
Analytics maturity curve: descriptive → diagnostic → predictive → prescriptive analytics

Product Rollout

Deployed across community health centres, high-footfall public locations, schools, corporations, and at-home settings
4T4TB platform rolled out as dedicated tuberculosis case-finding and management system
Health ATM kiosk integrated with FlynnCare Clinical Management System (CMS)

Proof Point: Catanduanes Province Deployment

Implementing Philippines' first province-wide integrated digital healthcare model
Combining Health Kiosks with PhilHealth-accredited FlynnCare CMS
Screening covers lipid profile, HbA1c, general and mental health, hearing, eye health, and cardiac checks
Received PhilHealth YAKAP accreditation as certified service provider

FMV Prime - tabletop qPCR system for tuberculosis and rifampicin resistance testing
AI-powered immunofluorescence analyser returning results in 10-15 minutes across hundred assays
Mini CubeLab - haematology, clinical chemistry, immunofluorescence and cell imaging in one robotic instrument

AI-powered Integrated Rehabilitation Centers

Next-generation concept bringing together rehabilitation, preventive wellness, functional fitness, recovery, healthy ageing and longevity services
Client journey: Assess, Analyze, Personalize, Rehabilitate, Optimize, Recover, Monitor, Prevent
Flagship format: 5,000-square-foot facility with nine functional zones
Plan to launch 20 centers in Malaysia over next two years

AI-Driven Ayurveda and Modern Medicine Initiative

Strengthened strategic collaboration to bring Vecura AI-enabled molecular research platform to India
Designed to support Indian pharmaceutical companies, biotechnology innovators, academic institutions, and research organizations
Aims to accelerate drug discovery, improve research productivity, and unlock new therapeutic opportunities

Promoter Group converted warrants and subscribed to preferential allotment in August
Infused approximately ₹59.67 crore of promoter capital into the Company
Increased promoter shareholding from 62.15% to 63.08%

Company commits to provide quarterly updates on progress and achievements
All material developments, financial results, and disclosure requirements will be communicated to stock exchanges and public timely

Document contains forward-looking statements subject to risks and uncertainties
Not an offer to sell or solicitation to buy any securities
Information based on management information and estimates, subject to change without notice